Bristol-Myers Squibb Company (BMY) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Bristol-Myers Squibb Company and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 1, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$65.31HealthcareAt close: Jul 31, 2026, 4:00 PM ET
NVO
Novo Nordisk A/S
$47.08HealthcareDelayed quote: Jul 31, 2026, 3:59 PM EDT
Total return — BMY vs NVO
growth of $100 · dividends reinvested · last 30yBMY +807.5%NVO +10806.6%NVO compounded faster
Log scale — wide-divergence pair
BMY NVO
BMY vs NVO: by the numbers
- •NVO is the larger company ($209.19B vs $133.37B market cap).
- •NVO trades at the lower trailing earnings multiple (11.01 vs 14.39 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (37.14% vs 18.87% net margin).
- •NVO grew revenue faster over the past five years (20.73% vs 2.08% CAGR).
- •NVO pays the higher dividend yield (3.83% vs 2.88%).
Metrics side by side
Valuation
| Metric | BMY | NVO |
|---|---|---|
| P/E ratio | 14.39 | 11.01 |
| Forward P/E | 9.88 | N/A |
| P/S ratio | 2.72 | 4.09 |
| P/B ratio | 5.99 | 6.69 |
| PEG ratio | 1.53 | 8.16 |
| EV / EBITDA | 9.93 | 8.62 |
| FCF yield | 9.20% | 2.31% |
Profitability
| Metric | BMY | NVO |
|---|---|---|
| Gross margin | 70.16% | 81.83% |
| Operating margin | 28.27% | 45.21% |
| Net margin | 18.87% | 37.14% |
| ROE | 41.59% | 60.74% |
| ROIC | 13.90% | 29.53% |
Dividends
| Metric | BMY | NVO |
|---|---|---|
| Dividend yield | 2.88% | 3.83% |
| Payout ratio | 54.34% | 49.80% |
Growth (annualized)
| Metric | BMY | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 2.08% | 20.73% |
| EPS CAGR (5Y) | 9.38% | 19.59% |
| FCF CAGR (5Y) | -0.69% | -5.86% |
| Total return CAGR (5Y) | 3.38% | 2.46% |
Frequently asked
- Which has the lower trailing P/E, BMY or NVO?
- NVO has the lower trailing P/E: BMY trades at 14.39 and NVO at 11.01. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or NVO?
- Over the past five years, NVO grew revenue faster — BMY at a 2.08% CAGR versus NVO at 20.73%.
- Does BMY or NVO pay a bigger dividend?
- BMY yields 2.88% and NVO yields 3.83% based on trailing dividends and the latest price.
- Is BMY or NVO more profitable?
- NVO runs the higher net margin — BMY at 18.87% versus NVO at 37.14%.
- How have BMY and NVO total returns compared?
- Over the past 10 years, BMY delivered 2.19% and NVO delivered 7.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioNovo Nordisk A/S P/E ratioBristol-Myers Squibb dividend yieldNovo Nordisk A/S dividend yieldBristol-Myers Squibb ROENovo Nordisk A/S ROEBristol-Myers Squibb operating marginNovo Nordisk A/S operating marginBristol-Myers Squibb revenue growthNovo Nordisk A/S revenue growthBristol-Myers Squibb free cash flowNovo Nordisk A/S free cash flow
Bristol-Myers Squibb & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 1, 2026.